ImmunityBio, Inc. Quarterly Debt-to-equity in % from Q1 2016 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: ImmunityBio, Inc. quarterly Debt-to-equity history and growth rate from Q1 2016 to Q3 2024.
ImmunityBio, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -163 %, a 4.66% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	-163	+7.96	+4.66%	Sep 30, 2024
Q2 2024	-174	-7.88	-4.73%	Jun 30, 2024
Q1 2024	-170	+6.23	+3.54%	Mar 31, 2024
Q4 2023	-173	+15.3	+8.12%	Dec 31, 2023
Q3 2023	-171	+37.2	+17.9%	Sep 30, 2023
Q2 2023	-167	+51.3	+23.6%	Jun 30, 2023
Q1 2023	-176	+67.3	+27.7%	Mar 31, 2023
Q4 2022	-188	+59.7	+24.1%	Dec 31, 2022
Q3 2022	-208	+28.9	+12.2%	Sep 30, 2022
Q2 2022	-218	+154	+41.4%	Jun 30, 2022
Q1 2022	-243	-6.5K	-104%	Mar 31, 2022
Q4 2021	-248	-388	-276%	Dec 31, 2021
Q3 2021	-237	-314	-408%	Sep 30, 2021
Q2 2021	-372	-449	-581%	Jun 30, 2021
Q1 2021	6.25K	+6.17K	+7679%	Mar 31, 2021
Q4 2020	140	+67.7	+93.2%	Dec 31, 2020
Q3 2020	76.9	+53.6	+230%	Sep 30, 2020
Q2 2020	77.4	+52.5	+211%	Jun 30, 2020
Q1 2020	80.4	+55.9	+227%	Mar 31, 2020
Q4 2019	72.7	+51.2	+238%	Dec 31, 2019
Q3 2019	23.3	+6.2	+36.3%	Sep 30, 2019
Q2 2019	24.9	+9.32	+59.7%	Jun 30, 2019
Q1 2019	24.6	+8.09	+49.1%	Mar 31, 2019
Q4 2018	21.5	+6.79	+46.1%	Dec 31, 2018
Q3 2018	17.1	+4.1	+31.5%	Sep 30, 2018
Q2 2018	15.6	+5.08	+48.2%	Jun 30, 2018
Q1 2018	16.5	+9.32	+130%	Mar 31, 2018
Q4 2017	14.7	+8.94	+154%	Dec 31, 2017
Q3 2017	13	+8.45	+186%	Sep 30, 2017
Q2 2017	10.5	+7.18	+214%	Jun 30, 2017
Q1 2017	7.15	+4.03	+129%	Mar 31, 2017
Q4 2016	5.81			Dec 31, 2016
Q3 2016	4.55			Sep 30, 2016
Q2 2016	3.35			Jun 30, 2016
Q1 2016	3.12			Mar 31, 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.